These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 21642872)

  • 21. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
    Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
    Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
    Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
    Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M
    Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
    Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
    Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
    Filiberti R; Marroni P; Spigno F; Merlo DF; Mortara V; Caruso P; Cioè A; Michelazzi L; Bruzzone A; Bobbio B; Simonassi C; Del Corso L; Galli R; Racchi O; Dini G; Linares R; Mencoboni M
    Oncology; 2014; 86(1):33-43. PubMed ID: 24401539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
    Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
    J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
    Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
    Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
    Wheatley-Price P; Yang B; Patsios D; Patel D; Ma C; Xu W; Leighl N; Feld R; Cho BC; O'Sullivan B; Roberts H; Tsao MS; Tammemagi M; Anraku M; Chen Z; de Perrot M; Liu G
    J Clin Oncol; 2010 Jul; 28(20):3316-22. PubMed ID: 20498407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
    De Santi C; Pucci P; Bonotti A; Melaiu O; Cipollini M; Silvestri R; Vymetalkova V; Barone E; Paolicchi E; Corrado A; Lepori I; Dell'Anno I; Pellè L; Vodicka P; Mutti L; Foddis R; Cristaudo A; Gemignani F; Landi S
    Occup Environ Med; 2017 Jun; 74(6):456-463. PubMed ID: 28343162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New diagnostic markers for malignant pleural mesothelioma].
    Grigoriu BD; Grégoire M; Chahine B; Scherpereel A
    Bull Cancer; 2008 Feb; 95(2):177-84. PubMed ID: 18304902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
    Hollevoet K; Nackaerts K; Thimpont J; Germonpré P; Bosquée L; De Vuyst P; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
    Am J Respir Crit Care Med; 2010 Mar; 181(6):620-5. PubMed ID: 20075387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble mesothelin-related protein--a blood test for mesothelioma.
    Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
    Lung Cancer; 2005 Jul; 49 Suppl 1():S109-11. PubMed ID: 15950789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population.
    Park EK; Thomas PS; Creaney J; Johnson AR; Robinson BW; Yates DH
    Clin Chem Lab Med; 2010 Jun; 48(6):869-74. PubMed ID: 20345230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
    Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T
    Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.
    Cui A; Jin XG; Zhai K; Tong ZH; Shi HZ
    BMJ Open; 2014 Feb; 4(2):e004145. PubMed ID: 24566531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
    Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
    Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
    Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M
    Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma.
    Franko A; Dolzan V; Kovac V; Arneric N; Dodic-Fikfak M
    Dis Markers; 2012; 32(2):123-31. PubMed ID: 22377706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
    Luo L; Shi HZ; Liang QL; Jiang J; Qin SM; Deng JM
    Respir Med; 2010 Jan; 104(1):149-56. PubMed ID: 19945835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.